‘Innovations in Community Health’ program addresses a growing need among patients
WHAT IT MEANS AND WHY IT’S IMPORTANT — Why is the news that CVS Caremark Charitable Trust has teamed up with the National Association of Community Health Centers important? $300 billion a year and an alarming rise in the number of Americans suffering from chronic diseases. That’s why.
(THE NEWS: CVS Caremark Charitable Trust, NACHC form ‘Innovations in Community Health’ program. For the full story, click here)
Annual excess healthcare costs because of medication nonadherence in the United States are estimated to be as much as $300 billion — yes, billion — annually.
Furthermore, more than half of Americans suffer from one or more chronic diseases, and that number is expected to grow in the next decade. Just take diabetes as one example, a disease that costs $174 billion annually, including $116 billion in direct medical expenses.
Nearly 26 million Americans have diabetes, according to estimates from the Centers for Disease Control and Prevention. In addition, an estimated 79 million U.S. adults have prediabetes, a condition in which blood-sugar levels are higher than normal, but not high enough to be diagnosed as diabetes. Prediabetes raises a person’s risk of Type 2 diabetes, heart disease and stroke.
In a study published in 2010, CDC projected that as many as 1-out-of-3 U.S. adults could have diabetes by 2050, if current trends continue.
Need more of a reason? Now factor in the recent Supreme Court ruling on healthcare reform that could put as many as 40 million uninsured Americans into the coverage rolls — and potentially into prescription drug coverage. It will drive a good number of patients to medical homes, and in theory, significantly increase the demand for maintenance prescriptions and other preventative or chronic healthcare services.
That’s what makes the multiyear partnership between the CVS Caremark Charitable Trust and the National Association of Community Health Centers so important as it will make grants available to community health centers across the country to support the development of innovative, community-based programs and initiatives to manage chronic diseases.
Funding through the grant program will support a variety of programs such as healthcare models that include education and tracking methods for promoting medication adherence for patients managing chronic diseases.
Clearly, there’s a need for greater access to healthcare and medical services. What are your thoughts on additional ways the industry can help meet this need and further improve the lives of patients?
Coca-Cola overhauls operating structure
ATLANTA — Coca-Cola has streamlined its operating structure and the senior leaders for those businesses, the company said.
Effective Jan. 1, 2013, Coca-Cola will organize around three major operating businesses: Coca-Cola International — which will consist of the company’s Europe, Pacific and Eurasia and Africa operations; Coca-Cola Americas — which will consist of the company’s North America and Latin America operations; and the Bottling Investments Group, which oversees the Coca-Cola-owned bottling operations outside of North America.
As part of the structure change, Ahmet Bozer, currently president of the Eurasia and Africa group, will be appointed president of Coca-Cola International; Steve Cahillane, currently president and CEO of Coca-Cola Refreshments, will be appointed president of Coca-Cola Americas; and Irial Finan will continue as president of BIG. All three executives will continue to report to Coca-Cola chairman and CEO Muhtar Kent.
"This is the right structure for the next phase of our journey toward achieving our 2020 vision," Kent said. "Over the last couple of years, we have systematically been adapting our business model to better address the changing demands of the global marketplace. We have a solid foundation and momentum in our business. Now is the time to take the next step in our evolution. By consolidating leadership of our global operations under two large, but similar sized geographic regions and BIG, we will streamline reporting lines, intensify our focus on key markets and create a structure that leverages synergies and gives us flexibility to strategically adjust our business within those geographies in the future."
Takeda resubmits diabetes drug applications
DEERFIELD, Ill. — Drug maker Takeda Pharmaceutical has resubmitted regulatory approval applications for two drugs designed to treat diabetes, the company said.
Takeda announced the resubmission to the Food and Drug Administration of applications for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in the Takeda drug Actos.
The applications were submitted after the company received a complete response letter from the FDA for the drugs in April. A complete response letter means that the agency has finished reviewing an application, but questions remain that preclude final approval. Takeda’s resubmissions include additional data from three phase-3 clinical trials that the FDA had requested.